This is the mail archive of the
ecos-bugs@sourceware.org
mailing list for the eCos project.
We have a hot alert for morning. Big News just came out
- From: "Forrest" <Donn1 at js-scapes dot fsnet dot co dot uk>
- To: <cygwin-owner at sources dot redhat dot com>
- Date: Wed, 31 Aug 2005 14:36:00 -0800
- Subject: We have a hot alert for morning. Big News just came out
<html>
<body>
<table width=3D"654" border=3D"1" align=3D"center" cellpadding=3D"0" =
cellspacing=3D"0" bordercolor=3D"#000000">
<tr>
<td width=3D"650"><table width=3D"650" border=3D"0" align=3D"center" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" style=3D"padding:8px" height=3D"46" =
bgcolor=3D"#0000FF">
<p><font size=3D"4"><strong><font color=3D"#FFFFFF">EMERGING =
GROWTH ALERT</font></strong></p></td>
</tr>
<tr>
<td bgcolor=3D"#000000" style=3D"padding:2px">
<font color=3D"#FFFFFF">Issue: 101655</font></td>
<td bgcolor=3D"#000000" style=3D"padding:2px"><div =
align=3D"right">
<font color=3D"#FFFFFF">AUGUST 2005</font></div></td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:10px"><div =
align=3D"left"></div>
<div align=3D"left"></div>
<table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"0" cellspacing=3D"0">
<tr>
<td><table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" bgcolor=3D"#0000FF"><b><em>
<font size=3D"2" face=3D"Arial, Helvetica, sans-serif" =
color=3D"#FFFFFF">
Worldwide Biotech & Pharmaceutical Co</font></em></b><font =
color=3D"#FFFFFF" size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong><br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"2" =
color=3D"#FFFFFF">
Rapid Growth Alert</font></strong></td>
</tr>
<tr>
<td width=3D"53%"><font size=3D"2" face=3D"Arial, =
Helvetica, sans-serif">
Sy<b></b>mbol: </font></td>
<td width=3D"47%"><em><b>
<font face=3D"Arial, Helvetica, sans-serif" =
size=3D"2">WWBP</font></b></em></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">52 Week
Range</font></td>
<td>2.00 - 11.00</td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Sha<b></b>res
Float: </font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
25,000,000</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Current
Price:</font></td>
<td> <font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong>
$2.40</strong></font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">12
Mo.Target Price</font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">$22.00</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"> Growth
Rating</font></td>
<td>High</td>
</tr>
</table></td>
</tr>
</table>
<p><em>
<font color=3D"#FF0000" size=3D"4" face=3D"Arial, Helvetica, =
sans-serif"><strong>
Breaking News Alerts!<br>
<br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#FF0000">
Up</font><font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#CC0000">
</font></strong></em><b style=3D"color: #FF0000"><font size=3D"4">0.73
(24.33%)<br>
<br>
Get In While You Still Can!</font></b><em><strong><font face=3D"Arial, =
Helvetica, sans-serif" color=3D"#CC0000" size=3D"3"><br>
<br>
</font></strong><font size=3D"3" face=3D"Arial, Helvetica, sans-serif">
<b>Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'</b></font><font size=3D"2" =
face=3D"Arial, Helvetica, sans-serif"><br>
<br>
<font color=3D"#FF0000">Thursday August 25, 9:00 am ET <br>
</font><br>
<font color=3D"#0000FF"><b>Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China</b> </font><br>
<br>
<br>
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''<br>
ADVERTISEMENT<br>
<br>
<br>
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.<br>
<br>
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''<br>
<br>
<font color=3D"#0000FF"><b>About World Intellectual Property
Organization (WIPO)</b></font><br>
<br>
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.<br>
<br>
<font color=3D"#0000FF"><b>About Worldwide Biotech & Pharmaceutical =
Company</b></font><br>
<br>
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good =
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.<br>
<br>
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen =
and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing =
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.</font></p>
</ol> </em> </td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:15px"><p align=3D"justify">
<font color=3D"#FFFFFF">In November 2004, Financial Accounting Standards =
Board issued statement of Financial Accounting Standard No. 151, =
"Inventory Costs." The new statement amends Accounting Research Bulletin =
No. 43, Chapter 4, "Inventory Pricing," to clarify the accounting for =
abnormal amounts of idle facility expense, freight, handling costs, and =
wasted material. This statement requires that those items be recognized as =
current-period charges and requires that allocation of fixed production =
overheads to the cost of conversion be based on the normal capacity of the =
production facilities. This statement is effective for fiscal years =
beginning after June 15, 2005. We do not expect adoption of this statement =
to have a material impact on our financial condition or results of =
operations. <br>We are not aware of any known trends, events or =
uncertainties that have, or reasonably likely to have material impact on =
this short-term or long-term liquidity. We have no internal source of =
liquidity at the present time and do not generate revenue from sales, =
however, we intend to pursue internal sources of liquidity as explained =
above, through registration of various shares of stock on a registration =
statement to be filed with the Securities & Exchange Commission, or =
through traditional means of obtaining funds through various financial =
institutions. We are in need of additional funds to meet various =
anticipated capital expenditures which include research and development =
for drug-screening system for anti-HCV drugs and HBV vaccines, production =
of products for release into the market, mergers of companies that would =
align the Company's business plans, and various funds to market our =
technology and products to create interest in the market place. We will =
need to raise funds either through traditional sources of financing or =
through the sale of stock to meet these commitments. <br>As a result of =
these factors, we reported a net loss of $706,168 or $.02 per share for =
the three months ended March 31, 2005, as compared to a net loss of =
$85,667 or $.00 per share for the three months ended March 31, 2004. =
<br>For the six months ended June 30, 2005, general and administrative =
expenses were $170,313 as compared to $133,083 for the six months ended =
June 30, 2004, an increase of $37,230, or approximately 28%. In the 2005 =
period, we incurred additional marketing fees, travel-related expenses and =
other administrative expenses due to the continued implementation of our =
business plan. <br></font></p></td>
</tr>
</table></td>
</tr>
</table>
<br></body>
</html>